Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis
- Citation:
- Cancer Med vol 12 (7) 8211-8217
- Year:
- 2023
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- Alliance-data-source,-internal-user
- Status:
- Presented/Published
- Citation Status:
- collection
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- Yes
- Book Volume:
- 12
- Parents:
- 3400
- Children:
- None
- Pharmas:
- Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, Wyeth (HHSN261200800001E)
- Grants:
- U10CA18082, U10CA180882, U10CA180791, U10CA180833, UG1CA233191, UG1CA233290, UG1CA233331, UG1CA233339, UG1CA189960, P30 CA008748
- Corr. Author:
- Authors:
- Pallawi Torka Levi D. Pederson Michael V. Knopp David Poon Jun Zhang Brad S. Kahl Howard R. Higley Gary Kelloff Jonathan W. Friedberg Lawrence H. Schwartz Wyndham H. Wilson John P. Leonard Nancy L. Bartlett Heiko Schöder Amy S. Ruppert
- Networks:
- LAPS-MO011, LAPS-NY016, LAPS-OH007, NY018, PA121
- Study
- CALGB-50303
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-580603
- Phases:
- 3, 3
- Keywords:
- Deauville 5‐PS, interim PET, International Harmonization Project criteria, visual scoring system, ΔSUV